- Home
- JBHT vs RPRX Comparison
JBHT vs RPRX Comparison
Compare JBHT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBHT
- RPRX
- Stock Information
- Founded
- JBHT 1961
- RPRX 1996
- Country
- JBHT United States
- RPRX United States
- Employees
- JBHT N/A
- RPRX N/A
- Industry
- JBHT Trucking Freight/Courier Services
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- JBHT Industrials
- RPRX Health Care
- Exchange
- JBHT Nasdaq
- RPRX Nasdaq
- Market Cap
- JBHT 14.0B
- RPRX 15.6B
- IPO Year
- JBHT N/A
- RPRX 2020
- Fundamental
- Price
- JBHT $134.88
- RPRX $35.60
- Analyst Decision
- JBHT Buy
- RPRX Strong Buy
- Analyst Count
- JBHT 19
- RPRX 3
- Target Price
- JBHT $167.74
- RPRX $45.33
- AVG Volume (30 Days)
- JBHT 1.1M
- RPRX 4.1M
- Earning Date
- JBHT 10-14-2025
- RPRX 11-05-2025
- Dividend Yield
- JBHT 1.30%
- RPRX 2.47%
- EPS Growth
- JBHT N/A
- RPRX 54.86
- EPS
- JBHT 5.51
- RPRX 2.32
- Revenue
- JBHT $12,064,092,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- JBHT $1.37
- RPRX $35.01
- Revenue Next Year
- JBHT $5.21
- RPRX $3.14
- P/E Ratio
- JBHT $24.47
- RPRX $15.33
- Revenue Growth
- JBHT N/A
- RPRX 3.02
- 52 Week Low
- JBHT $122.79
- RPRX $24.05
- 52 Week High
- JBHT $200.40
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- JBHT 38.85
- RPRX 45.14
- Support Level
- JBHT $135.78
- RPRX $34.84
- Resistance Level
- JBHT $141.03
- RPRX $35.84
- Average True Range (ATR)
- JBHT 3.57
- RPRX 0.84
- MACD
- JBHT -0.85
- RPRX -0.08
- Stochastic Oscillator
- JBHT 7.38
- RPRX 47.39
About JBHT J.B. Hunt Transport Services Inc.
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.